Implication of prostaglandin receptors in the accumulation of osteoprotegerin in human osteoblast cultures.
OBJECTIVE
Prostaglandins are important mediators in bone metabolism and in pathologies such as rheumatoid arthritis and osteoarthritis. We investigated the roles of cyclooxygenases (COX) and prostaglandin receptors in the accumulation of osteoprotegerin (OPG) in the supernatants of human osteoblasts in culture.


METHODS
Three different cellular models were used, the human osteosarcoma cell lines MG-63 and Saos-2, and primary cultures of human osteoblasts. OPG concentrations were determined by ELISA.


RESULTS
RT-PCR analysis showed that, like primary human osteoblasts, MG-63 cells express DP, EP4, FP, IP, and TP receptors, whereas the Saos-2 cells lack IP. Concentration of OPG was highest in MG-63 cell supernatants (36 +/- 12.5 ng/ml), followed by human osteoblasts (12.77 +/- 2.2 ng/ml) and Saos-2 (3.6 +/- 0.76 ng/ml). COX inhibitors did not alter these values. Prostaglandin E2 and BW 245C (a synthetic DP receptor agonist) decreased OPG in the supernatants of human osteoblasts but not in immortalized cell lines. These effects were concentration-dependent and were inhibited by EP4 and DP receptor antagonists. Fluprostenol, an FP receptor agonist, increased the accumulation of OPG in MG-63 but not in primary human osteoblasts or Saos-2.


CONCLUSIONS
Our results show that activation of EP4 or DP receptors decreased the accumulation of OPG in supernatants of osteoblasts in culture, and suggest that these receptors could be interesting pharmacological targets in bone diseases. They also demonstrate important differences between primary osteoblasts and immortalized cell lines, both in the distribution and in the effects mediated by prostaglandin receptors.
Samadfam
Rana
R
Division of Rheumatology, Faculty of Medicine, Universitéde Sherbrooke, Fleurimont, Québec J1H 5N4, Canada.
Gallant
Maxime A
MA
Miousse
Marie-Claude
MC
Parent
Jean-Luc
JL
de Brum-Fernandes
Artur J
AJ
D002461:Cell Line, Transformed; D045744:Cell Line, Tumor; D015232:Dinoprostone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004797:Enzyme-Linked Immunosorbent Assay; D015870:Gene Expression / Q000187:drug effects; D006023:Glycoproteins / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D006827:Hydantoins / Q000494:pharmacology; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D053244:Osteoprotegerin; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics / Q000378:metabolism*; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D018124:Receptors, Tumor Necrosis Factor / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D004338:Drug Combinations; D006023:Glycoproteins; D006827:Hydantoins; D053244:Osteoprotegerin; D011461:Prostaglandins F, Synthetic; D012333:RNA, Messenger; D018160:Receptors, Cytoplasmic and Nuclear; D011982:Receptors, Prostaglandin; D018124:Receptors, Tumor Necrosis Factor; C506030:TNFRSF11B protein, human; C006326:fluprostenol; C030669:BW 245C; D011451:Prostaglandin-Endoperoxide Synthases; D015232:Dinoprostone